Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 Veterinary use  





2 Synthesis  





3 See also  





4 References  














Azaperone






فارسی
Bahasa Melayu

Português
Српски / srpski
Srpskohrvatski / српскохрватски
Türkçe
 

Edit links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 




In other projects  



Wikimedia Commons
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


Azaperone
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration
IM
ATCvet code
Pharmacokinetic data
MetabolismHepatic
Elimination half-life4 hours
Identifiers
  • 1-(4-fluorophenyl)-4-(4-pyridin-2-ylpiperazin-1-yl)butan-1-one

CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.015.197 Edit this at Wikidata
Chemical and physical data
FormulaC19H22FN3O
Molar mass327.403 g·mol−1
3D model (JSmol)
Melting point90 to 95 °C (194 to 203 °F)
  • Fc1ccc(cc1)C(=O)CCCN3CCN(c2ncccc2)CC3

  • InChI=1S/C19H22FN3O/c20-17-8-6-16(7-9-17)18(24)4-3-11-22-12-14-23(15-13-22)19-5-1-2-10-21-19/h1-2,5-10H,3-4,11-15H2 checkY

  • Key:XTKDAFGWCDAMPY-UHFFFAOYSA-N checkY

 ☒NcheckY (what is this?)  (verify)

Azaperone is a pyridinylpiperazine and butyrophenone neuroleptic drug with sedative and antiemetic effects, which is used mainly as a tranquilizerinveterinary medicine.[1] It is uncommonly used in humans as an antipsychotic drug.

Azaperone acts primarily as a dopamine antagonist but also has some antihistaminic and anticholinergic properties as seen with similar drugs such as haloperidol. Azaperone may cause hypotension and while it has minimal effects on respiration in pigs, high doses in humans can cause respiratory depression.

Veterinary use[edit]

The most common use for azaperone is in relatively small doses as a "serenic" (to reduce aggression) in farmed pigs, either to stop them fighting or to encourage sows to accept piglets. Higher doses are used for anesthesia in combination with other drugs such as xylazine, tiletamine and zolazepam. Azaperone is also used in combination with strong narcotics such as etorphineorcarfentanil for tranquilizing large animals such as elephants.[2] Use in horses is avoided as adverse reactions may occur.

The European Medicines Agency has established a maximum residue limit for azaperone when administered to pigs.[3]

Azaperone (under the brand name Stresnil) was approved for use in pigs in the USA in 1983, under NADA 115-732.[4]

Synthesis[edit]

52%:[5] Patent:[6] Improved method:[7] Radiolabelled:[8]

The alkylation of 2-chloropyridine (1) with piperazine gives 1-(pyridin-2-yl)piperazine [67980-77-2] (2). The attachement of the sidechain by reaction with 4-chloro-4'-fluorobutyrophenone [3874-54-2] (3) completed the synthesis of azaperone (4).

See also[edit]

References[edit]

  1. ^ Posner LP, Burns P (2013). "Sedative agents: tranquilizers, alpha-2 agonists, and related agents. Veterinary pharmacology and therapeutics. 2009:.". In Riviere JE, Papich MG (eds.). Veterinary Pharmacology and Therapeutics (9th ed.). Somerset: Wiley. pp. 337–380 (366). ISBN 978-1-118-68590-7.
  • ^ "The Elephant Formulary". Archived from the original on 2012-02-05. Retrieved 2007-04-30.
  • ^ "Azaperone Summary Report (2)" (PDF). European Medicines Agency. Committee for Veterinary Medicinal Products. November 1997. Archived from the original (PDF) on 2017-01-16. Retrieved 2017-01-15.
  • ^ "Rules and Regulations" (PDF). Federal Register. 48 (202): 48229. 18 October 1983. Retrieved 2017-01-15.
  • ^ Jaen, Juan C.; Caprathe, Bradley W.; Pugsley, Thomas A.; Wise, Lawrence D.; Akunne, Hyacinth (1993). "Evaluation of the effects of the enantiomers of reduced haloperidol, azaperol, and related 4-amino-1-arylbutanols on dopamine and .sigma. receptors". Journal of Medicinal Chemistry. 36 (24): 3929–3936. doi:10.1021/jm00076a022.
  • ^ Janssen Paul Adriaan Jan, U.S. patent 2,958,694 (1960).
  • ^ Taghizadeh, M. J., Mohammadnia, M. S., Ghalkhani, M., Sohouli, E. (April 2022). "Improved Method for the Total Synthesis of Azaperone and Investigation of Its Electrochemical Behavior in Aqueous Solution". Chemical Research in Chinese Universities. 38 (2): 546–551. doi:10.1007/s40242-021-1061-2. ISSN 1005-9040. S2CID 235614834.
  • ^ Soudijn, W.; van Wijngaarden, I. (1968). "A rapid and convenient method for the synthesis of labelled tertiary amines". Journal of Labelled Compounds. 4 (2): 159–163. doi:10.1002/jlcr.2590040209.

  • Retrieved from "https://en.wikipedia.org/w/index.php?title=Azaperone&oldid=1212511053"

    Categories: 
    Butyrophenone antipsychotics
    Piperazines
    2-Pyridyl compounds
    Typical antipsychotics
    Hidden categories: 
    Articles with short description
    Short description matches Wikidata
    Articles with changed CASNo identifier
    Articles with changed EBI identifier
    ECHA InfoCard ID from Wikidata
    Drugs with no legal status
    Drugboxes which contain changes to verified fields
     



    This page was last edited on 8 March 2024, at 06:33 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki